Synthesis and antitumor properties of selenocoxib‐1 against rat prostate adenocarcinoma cells
Open Access
- 21 April 2010
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 127 (1), 230-238
- https://doi.org/10.1002/ijc.25033
Abstract
Hormone refractory prostate cancer poses a huge problem and standard of care chemotherapy has not been very successful. We used a novel strategy to combine properties of 2 well-studied class of compounds (selenium and COX-2 inhibitor) and examined the resulting effectiveness against prostate cancer. Bearing in mind that sulfonamide moiety and pyrazole ring is important for the proapoptotic activity of Celecoxib, we synthesized a selenium derivative, Selenocoxib-1, by modifying Celecoxib at position 3 of the pyrazole ring. The PAIII cells derived from a metastatic prostate tumor that arose spontaneously in a Lobund-Wistar (LW) rat were used to examine the efficacy of Selenocoxib-1 in vitro. In addition, human metastatic prostate cancer cells, PC-3M, were tested for antitumor effect of Selenocoxib-1 in vitro. The IC50 in PAIII and PC-3M cells for Selenocoxib-1 was about 5 μM, while for Celecoxib it was more than 20 μM. Selenocoxib-1 induced apoptosis in a dose-dependent manner in the PAIII cells. COX-2 expression in PAIII cells was downregulated by Celecoxib and Selenocoxib-1 at 20 and 5 μM, respectively; the COX-2 activity was, however, not affected by Selenocoxib-1. Following treatment with Selenocoxib-1, PAIII cells resulted in dose-dependent decrease in HIF-1α, p-AKT and Bcl-2 levels. A reduction in weights was observed in subcutaneous tumors produced by PAIII cells pretreated with Selenocoxib-1 as compared to Celecoxib in LW rats. Further, following 1 week Selenocoxib-1 treatment of PAIII tumors resulted in significant reduction of tumor weights. This study demonstrates that Selenocoxib-1 is more effective against prostate cancer than Celecoxib.Keywords
This publication has 36 references indexed in Scilit:
- Targeting Akt3 Signaling in Malignant Melanoma Using IsoselenocyanatesClinical Cancer Research, 2009
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other CancersJAMA, 2009
- Synthesis and Anticancer Activity Comparison of Phenylalkyl Isoselenocyanates with Corresponding Naturally Occurring and Synthetic IsothiocyanatesJournal of Medicinal Chemistry, 2008
- Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort studyThe Lancet Oncology, 2008
- Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or seleniteCarcinogenesis: Integrative Cancer Research, 2008
- Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II studyBritish Journal of Cancer, 2007
- Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenaseBiochemical and Biophysical Research Communications, 2004
- A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate CancerMayo Clinic Proceedings, 2002
- Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study GroupJAMA, 1996
- Inhibitory effects of selenium on the growth of du-145 human prostate carcinoma cells in vitroBiochemical and Biophysical Research Communications, 1985